Acquisitions - Additional Information 1 (Details) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
|
| Business Combination [Line Items] | ||||
| Change in the estimated fair value of contingent consideration | $ 27,107 | $ 8,164 | ||
| Cobalt Biomedicine, Inc | Acquisition Agreement | Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense | ||||
| Business Combination [Line Items] | ||||
| Change in estimated fair value of success payment | $ 7,200 | $ 3,600 | 5,300 | 3,700 |
| Change in the estimated fair value of contingent consideration | $ 16,400 | $ 6,300 | $ 27,100 | $ 8,200 |
| X | ||||||||||
- Definition Gain expense in connection with change in estimated fair value of success payment liabilities. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of increase (decrease) in value of liability in contingent consideration arrangement in business combination, including, but not limited to, difference arising upon settlement. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|